The University of Texas Southwestern Medical Center

Harold C. Simmons Comprehensive Cancer Center

Dallas, TX
Website
(831) 888-0898Refer Patient

Sorting 4 by

Accepting patients

TRIDENT-1

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

CARE Study

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2
  • Has results
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Not currently accepting

Genomically-Guided Treatment Trial in Brain Metastases
Learn more
  • PI3K Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • CDK6
  • Phase 2

Accepting patients

NCI-COG Pediatric MATCH

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Learn more
  • ALK Inhibitor
  • EphA2 Inhibitor
  • Phase 2